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creased fibrotic reaction and increased cellular senescence after stimulation with cholangiocyte supernatant
with reduced vimentin levels.
Interpretation: Our study demonstrated that knockdown of vimentin reduces mesenchymal phenotype of
cholangiocytes, which leads to decreased biliary senescence and liver fibrosis. Inhibition of vimentin may be a
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Research in context
Evidences before this study
Epithelial-to-mesenchymal transition (EMT) is a phenomenon that
has been identified in several types of chronic fibrotic disorders,
where epithelial cells acquire mesenchymal features, thereby con-
tributing to the fibrogenic process. Vimentin is a type III intermedi-
ate filament existing in mesenchymal cells. Induction of vimentin
in epithelial cells results in several important features of EMT, in-
cluding the adoption of a mesenchymal shape, loss of desmo-
somes and increased focal adhesion and cell motility.
Added value of this study
In the current study, we have reinforced the notion that there was
enhanced mesenchymal phenotypes of cholangiocytes in Mdr2−/−
compared to WT mice, which may contribute to the population of
portal fibroblasts. Our data further suggest that vimentin could be
a biomarker of liver fibrosis. Moreover, using an experimental
mouse model of liver fibrosis and specimens from human livers,
we have elucidated the role of vimentin in these settings. We
have found that knockdown of vimentin in Mdr2−/− mice reduces
mesenchymal phenotype of cholangiocytes, ductular reaction, bil-
iary senescence, liver fibrosis, and pro-fibrotic activation of HSCs
by a paracrine mechanism.
Implications of all the available evidences
Our results complete the previous studies and confirm that
there was increased immunoreactivity of vimentin and decreased
CK-19 staining intensity in liver sections from PSC patients com-
pared to healthy controls. Besides, we provide evidence that
knockdown of vimentin during liver damage generates a response
that seeks to counteract the ductular reaction and pro-fibrotic
responses. Our data could be the basis for new CD5L-based thera-
pies targeting liver fibrosis. Thus, inhibition of vimentin expres-
sion may be a key therapeutic target in the treatment of
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T wild-typeW1. Introduction
Cholangiopathies, such as Primary Biliary Cholangitis (PBC) and
Primary Sclerosing Cholangitis (PSC), are cholestatic liver diseases
(targeting intra- and extra-hepatic cholangiocytes) that are charac-
terized by chronic inflammation leading to biliary damage/prolifera-
tion and ultimately liver fibrosis. Epithelial-mesenchymal transition
(EMT) is an event by which epithelial cells lose their native charac-
teristics and display functional properties of mesenchymal cells.
Recent studies show that EMT may play an important role in the de-
velopment and progression of liver fibrosis. Immunostaining of liver
sections from patients with cholangiopathies demonstrated a loss of
epithelial markers including E-cadherin, and the acquisition of
S100a4 (the human homologue of fibroblast-specific protein-1, FSP-
1) and other mesenchymal markers in cholangiocytes within fibrotic
portal tracts [1–3]. Interestingly, the concept of EMT has become one
of the most controversial issues in liver fibrosis research [4,5]. As
most studies supporting the occurrence of EMT in cholangiocytes
are based essentially on a morphological approach, results from
two linage tracing studies show evidence against the concept of
cholangiocyte EMT in bile duct ligated (BDL) and carbon tetrachlo-
ride (CCl4) models [6,7].
Vimentin is a type III intermediate filament that has been found
in various types of mesenchymal cells during the developmental
stages [8,9]. The importance of intermediate filaments in regulating
physiological properties of cells is becoming widely recognized in
functions ranging from cell motility to signal transduction [8,9]. In-
duction of vimentin in epithelial cells results in several important
features of EMT, including the adoption of a mesenchymal shape,
mesenchymal cells, those cells exhibit reduced motility and adopt
an epithelial-like shape [9]. It has been shown that vimentin is asso-
ciated with cancer invasion and poor prognosis in numerous types of
cancers, including breast, lung and prostate cancer as well as mela-
noma, and serves as a potential target for cancer therapy [10,11].
Although vimentin expression has been found in liver cells that
undergo EMT, the precise role of vimentin in the regulation of liver
fibrosis is undefined.
We have previously shown that ductular reaction and biliary senes-
cence are increased in cholestatic liver injuries, including PBC and PSC,
which leads to paracrine activation of hepatic stellate cells (HSCs) and
increased liver fibrosis [12,13]. The aims of the present study were to:
(i) evaluate whether there is enhanced mesenchymal phenotype of
cholangiocytes in the Mdr2−/−model of PSC and human PSC samples;
(ii) characterize the role of vimentin in the pathogenesis of biliary dam-
age and liver fibrosis in PSC; and (iii) compare the expression of mesen-
chymal, fibrotic and senescent markers in the Mdr2−/− mice with or
without vimentin silencing.
2. Materials and methods
2.1. Materials
Reagents were purchased from Sigma Chemical Co. (St. Louis, MO)
unless otherwise stated. Cell culture reagents and media were obtained
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SMA (ab5694), collagen type I alpha 1 (Col1a1, ab21286), desmin
(ab185033), E-cadherin (ab11512), HNF4α (ab201460), VEGFA
(ab52917), vimentin (ab92547) and cyclin-dependent kinase inhibitor
1A (p16, ab189043) were purchased from Abcam (Burlingame, CA);
cytokeratin-19 (CK-19) antibody was obtained from Developmental
Studies Hybridoma Bank (Iowa City, IA); F4/80 and vimentin antibodies
were purchased fromCell Signaling (Denver,MA). ELISA kits tomeasure
transforming growth factor-β1 (TGF-β1) levels in serum and
cholangiocyte supernatant were purchased from Abcam (Burlingame,
CA). RNA was extracted using the mirVana miRNA Isolation Kit from
ThermoFisher Scientific and reverse transcribed with the iScript™
cDNA Synthesis Kit from Bio-Rad (Hercules, CA). All primer information
for qPCR is listed in Supplemental Table 1.
2.2. Animal models
All animal procedures were performed in accordancewith protocols
approved by the Baylor Scott & White Research Institute CTX IACUC.
Male Mdr2−/− mice (12 wk. age, 25–30 g) were originally purchased
from Jackson Laboratories (Bar Harbor, ME); the colonies were
established in our facility. FVB/NJ mice (WT control for Mdr2−/−
mice) were purchased from Jackson Laboratories. All micewere housed
in a temperature-controlled environment (22 °C) with 12:12-h light-
dark cycles. Mdr2−/− mice (n = 6) were treated with Vivo-
Morpholino sequences of vimentin (5′-ACACAGACCTGGTAGACATGG
CTTC-3′) or mismatched Morpholino (5′-ACAGACACCTCGTACACATCG
CTTC-3′) (Gene Tools LCC, Philomath, OR) by two tail vein injections
for 1 week (30 mg/kg BW). This approach minimizes the amount of
Vivo-Morpholino that circulates outside of the liver after slow infusion
into the portal vein [15–17]. Mice were euthanized, and tissues were
collected 7 days after the treatment [18,19]. In all groups, liver and
body weight were measured and liver to body weight ratio was calcu-
lated (index of liver cell growth) [20].
2.3. Isolation of mouse cholangiocytes and HSCs
Mouse cholangiocytes were isolated as described using a monoclo-
nal antibody (IgG2a; provided by R. Faris, Brown University, Rhode Is-
land, RI) against an unidentified membrane antigen expressed by all
intrahepatic cholangiocytes [16,21]. Cell viability (N97%) was assessed
by trypan blue exclusion.MouseHSCswere isolated by laser capturemi-
crodissection (LCM) using an antibody against desmin (marker of HSCs)
[12,22,23].
2.4. Evaluation of epithelial andmesenchymalmarkers in liver sections, iso-
lated cholangiocytes and HSCs
We measured: (i) immunoreactivity of vimentin and other EMT
markers (E-cadherin and S100a4) in liver sections by immunohisto-
chemistry and/or immunofluorescence co-stained with a cholangiocyte
marker (CK-19) or HSCmarker (desmin); (ii) the expression of mesen-
chymal markers (N-cadherin and S100a4) by qPCR in isolated
cholangiocytes. qPCR was performed using RT2 SYBR Green/ROX quan-
titative PCR master mix with the Applied Biosystems ViiA7 real-time
PCR system (Life Technologies; Carlsbad, CA) according to themanufac-
turer's protocol.
2.5. Measurement of liver histology, serum chemistry and ductular reac-
tion/intrahepatic bile duct mass (IBDM)
Liver histologywas evaluated in paraffin-embedded liver sections (4
μm) stained with hematoxylin and eosin (H&E). Observations were
processed in a blinded fashion by a board-certified pathologist. The
serum levels of serum glutamic oxaloacetic (SGOT) and alanine amino-
transferase (SGPT) and alkaline phosphatase (ALP) were measured byIDEXXCatalystOne Chemistry Analyzer andVetLab Station (Westbrook,
ME). Ductular reaction was evaluated in formalin-fixed, paraffin-
embedded liver sections (4 μm, 10 different fields analyzed for each
sample from three different animals) by immunohistochemistry for
CK-19 [16]. IBDM was calculated as area occupied by CK-19-positive
bile ducts/total area in VisioPharm software (Westminister, CO). Sec-
tions were examined by using the Olympus cellSens software (Olym-
pus, Japan).2.6. Measurement of liver fibrosis in liver sections, cholangiocytes and total
liver
Liver fibrosis was assessed by Sirius red staining to quantify collagen
deposition in liver sections [14]. Following Sirius red staining, slides
were scanned by a digital scanner (SCN400; LeicaMicrosystems, Buffalo
Grove, IL) and quantified by the Image-Pro Premier 9.1 (Media Cyber-
netics, Inc., Rockville, MD). In addition, immunofluorescence staining
was performed for Col1a1 co-stained with CK-19 and desmin in frozen
liver sections (8 μm). Immunofluorescent staining was visualized using
Leica TCS SP5 X system (Leica Microsystems Inc.) and Olympus F300
from Texas A&M Integrated Microscopy Imaging Laboratory. We also
measured the expression of Col1a1, Fn1 and TGF-β1 in isolated
cholangiocytes and total liver samples by qPCR.2.7.Measurement of biliary senescence in liver sections, cholangiocytes and
HSCs
Biliary senescencewas evaluated in frozen liver sections (10 μm) by:
(i) staining for senescence-associated-β-galactosidase (SA-β-gal) using
cellular senescence assay kit (MilliporeSigma, Billerica, MA); and (ii)
immunofluorescence for p16 (co-stained with CK-19). SA-β-gal stain-
ing was quantified as area occupied by SA-β-gal-positive bile ducts/
total area in VisioPharm software (Westminister, CO). The expression
of the senescent genes p16 and p21 was evaluated in purified
cholangiocytes and LCM-isolated HSCs by qPCR [12].2.8. Measurement of inflammation and angiogenesis in liver sections
Hepatic inflammation and angiogenesis were evaluated in formalin-
fixed, paraffin-embedded liver sections (4 μm, 10 different fields ana-
lyzed for each sample from three different animals) by immunohisto-
chemistry for F4/80 and VEGF-A, respectively. Quantitative analysis of
staining was performed using VisioPharm software (Westminister,
CO). Sections were examined by using the Olympus cellSens software
(Olympus, Japan).2.9. Measurement of epithelial and mesenchymal markers in human PSC
patients
The coded human liver specimens were obtained through the Liver
Tissue Procurement and Distribution System (Minneapolis, MN) as de-
scribed previously [24]. In addition, liver tissues from patients with
end stage PSC were obtained from the explant during liver transplanta-
tion. Control liver samples were from patients with no known history of
chronic liver diseases and collected during abdominal surgeries for var-
ious causes. The study protocol to obtain liver tissues were approved by
the Institutional Review Board at the Indiana University Purdue Univer-
sity Indianapolis. The sources of the human samples are shown in Sup-
plementary Table 2. The expression of vimentin and other EMTmarkers
was evaluated by qPCR, immunohistochemistry/immunofluorescence
or immunoblots in control and PSC patients. Protein expression was
normalized to GAPDH and quantified using the LI-COR Image Studio
software.
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The in vitro studies were performed in the following cell lines:
human intrahepatic biliary epithelial cells, (HIBEpiC, ScienCell, Carlsbad,
USA), human PSC patient-derived cholangiocytes (hPSCL, a gift from N.
LaRusso, Mayo Clinic, Rochester, MN), and human hepatic stellate cells
(HHSteCs, ScienCell, Carlsbad, USA) [21,25]. The expression of vimentin
was evaluated by immunofluorescence in hPSCL and HIBEpiC (control
for hPSCL). To examine the impact of vimentin in epithelial mesenchy-
mal crosstalk, HIBEpiC were seeded on six-well plates to approximately
60% to 70% confluence in complete medium containing 5% fetal bovine
serum and then changed to reduced-serum (2%) medium with control
or vimentin CRISPR/Cas9 KO plasmid transfection (Santa Cruz, Dallas,
TX) according to the manufacturer's protocol. After 24 h, recombinant
human TGF-β1 (R&D System, Minneapolis, MN) was added to the cul-
ture at a final concentration of 2.5 ng/ml to inducemesenchymal transi-
tion. The cells were incubated for 72 h before harvesting and subjected
to qPCR experiments as described below. In basal HIBEpiC and control or
vimentin CRISPR/Cas9 KO plasmid transfected HIBEpiC with/without
TGF-β1 stimulation, we measured the mRNA expression of EMT
markers (vimentin and E-cadherin), fibrotic markers (Col1a1 and Fn1)
and senescent markers (p16 and p21) by qPCR. HHSteCs were incu-
bated for 12 h at 37 °C with the supernatant of cholangiocytes purified
from our experimental groups of mice before measuring the expression
of E-cadherin, fibrotic markers (Col1a1, Fn1 and TGF-β1) and senescent
markers (p16 and p21) by qPCR.
2.11. Statistical analysis
All data are expressed as the mean ± SEM. Differences between
groups were analyzed by Student's unpaired t-test when two groups
were analyzed or one-way ANOVA (followed by an appropriate post
hoc test) when more than two groups were analyzed. A value of p b
.05 was considered significant.
3. Results
3.1. Evaluation of epithelial and mesenchymal phenotypes in liver sections,
isolated cholangiocytes and HSCs
By immunohistochemistry and/or immunofluorescence in liver sec-
tions from WT and Mdr2−/−mice, we observed enhanced immunore-
activity of vimentin in periductular area from Mdr2−/− compared to
WT mice (Fig. 1a–b). Interestingly, although CK-19-positive
cholangiocytes are surrounded by vimentin-positive cells, no merging
signals between vimentin and CK-19 could be observed. To evaluate
the role of vimentin in the pathogenesis of cholestatic liver injury, we
performed experiments aimed to reduce the hepatic expression of
vimentin in Mdr2−/− mice. In Mdr2−/− mice treated with vimentin
Vivo-Morpholino, there was a significant decrease in vimentin expres-
sion compared to Mdr2−/− mice treated with mismatch-Morpholino
treated mice; no significant changes were observed between Mdr2−/−
mice and Mdr2−/−mice treated with mismatch-Morpholino (Fig. 1a–
b). Similar changes were observed by immunofluorescence for CK-19
with another commonly used mesenchymal marker, S100a4 (Supple-
mentary Fig. 1a). We then evaluated the expression of other EMT
markers to see the knockdown effect of vimentin. Interestingly, there
was a significant reduction in N-cadherin and S100a4 expression in
cholangiocytes from Mdr2−/− mice treated with vimentin Vivo-
Morpholino compared to Mdr2−/− and Mdr2−/− mismatched mice
(Fig. 1c). In addition, by immunofluorescence in liver sections, we ob-
served a reduction of E-cadherin immunoreactivity (co-localized with
CK-19) in Mdr2−/−mice compared with WT mice (Fig. 1d). However,
there was enhanced E-cadherin expression in Mdr2−/− mice treated
with vimentin Vivo-Morpholino (Fig. 1d).Previous studies have shown that quiescent hepatic stellate cells
(HSCs) are capable of transdifferentiation into myofibroblastic HSCs
during the progression of liver fibrosis and gain mesenchymal pheno-
type [26,27]. We also evaluated the expression change of E-cadherin
and vimentin in HSCs by co-staining with desmin, the HSC marker
[13,23,28]. With the treatment of vimentin Vivo-Morpholino, we ob-
served less co-expression of desmin/vimentin and increased co-
localization of desmin/E-cadherin compared to Mdr2−/−mice, indicat-
ing the HSCs are less myofibroblastic with the knockdown of vimentin
(Supplementary Fig. 1b–c).
3.2. Knockdown of vimentin ameliorates liver damage, ductular reaction
and intrahepatic bile duct mass (IBDM)
By H&E staining, histopathological changes of liver damagewere ob-
served in Mdr2−/− compared to WT mice, which were ameliorated in
Mdr2−/− mice treated with vimentin Vivo-Morpholino (Fig. 2a).
While liver sections of Mdr2−/−mice and Mdr2−/−mismatched mice
showed both early and focal complete portal-portal bridging fibrosis
and moderate to marked ductular reaction, liver sections of Mdr2−/−
mice treated with vimentin Vivo-Morpholino showed early portal-
portal bridging fibrosis and mild ductular reaction. Interestingly,
serum levels of SGOT, SGPT, and ALPwere higher inMdr2−/− compared
with WT mice, but decreased in Mdr2−/−mice treated with vimentin
Vivo-Morpholino compared to Mdr2−/− mice (Table 1). In addition,
there was a significant increase in IBDM fromMdr2−/−mice compared
toWTmice,whichwas reduced inMdr2−/−mice treatedwith vimentin
Vivo-Morpholino (Fig. 2b); no significant changes in IBDM were ob-
served between Mdr2−/− mice and Mdr2−/− mismatched mice
(Fig. 2b).
3.3. Vimentin morpholino treatment decreases liver fibrosis
Collagen deposition was increased in Mdr2−/− compared to WT
mice but was significantly decreased in Mdr2−/− mice treated with
vimentin Vivo-Morpholino compared to Mdr2−/− and Mdr2−/− mis-
matched mice (Fig. 3a). By immunofluorescence, there was en-
hanced immunoreactivity for Col1a1 in cholangiocytes and HSCs
(co-stained with CK-19/desmin, respectively) from Mdr2−/− com-
pared to WT mice, immunoreactivity that was reduced in Mdr2−/−
mice treated with vimentin Vivo-Morpholino (Fig. 3b). Furthermore,
in isolated cholangiocytes, the expression of fibrosis markers
(Col1a1, TGF-β1 and α-SMA) was significantly increased in
Mdr2−/− compared to WT mice but decreased in Mdr2−/− mice
treated with vimentin Vivo-Morpholino (Fig. 3c). Furthermore,
TGFβ-1 levels were significantly increased in serum and
cholangiocyte supernatants collected from Mdr2−/− mice compared
with WT mice but decreased in Mdr2−/− mice treated with
vimentin Vivo-Morpholino (Table 1). These findings, along with the
above data, indicate that knockdown of vimentin reduces mesenchy-
mal phenotype of cholangiocytes and decreases the fibrotic reaction
of Mdr2−/− mice.
3.4. Knockdown of vimentin reduces biliary senescence, inflammation and
angiogenesis
By SA-β-gal staining in liver sections, we found enhanced biliary se-
nescence from Mdr2−/− compared with WT mice, which was signifi-
cantly decreased in Mdr2−/− mice treated with vimentin Vivo-
Morpholino (Fig. 4a). There was enhanced immunoreactivity for p16
in cholangiocytes (co-stained with CK-19) from Mdr2−/− mice com-
pared with WT mice, immunoreactivity that was reduced in Mdr2−/−
mice treated with vimentin Vivo-Morpholino (Fig. 4b). There was en-
hanced expression of p16 and p21 in cholangiocytes from Mdr2−/−
mice compared to WT mice, which decreased in Mdr2−/−mice treated
with vimentin Vivo-Morpholino (Fig. 4c). Conversely, we observed
ab
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134 T. Zhou et al. / EBioMedicine 48 (2019) 1 –14203decreased expression of p16 and p21 in LCM-isolated HSCs from
Mdr2−/− mice, which was significantly elevated in Mdr2−/− mice
treated with vimentin Vivo-Morpholino (Fig. 4d). In addition, as indi-
cated by the immunohistochemistry for F4/80 and VEGFA, knockdown
of vimentin also reduced hepatic inflammation and angiogenesis in
Mdr2−/−mice (Supplementary Figs. 2–3).3.5. Expression of EMT markers in human PSC patients and isolated PSC
patient-derived cholangiocytes
By qPCR, we observed that the mRNA expression of vimentin and
S100a4 was significantly higher in PSC patients compared to healthy
controls, whereas the expression of E-cadherin and N-cadherin showed
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(Fig. 5a, Supplementary Table 2). In addition, there was increased im-
munoreactivity of vimentin expression and decreased CK-19 staining
intensity in liver sections from early stage PSC patient compared to
healthy control (Fig. 5b). Upregulation of vimentin/CK-19 expression
was significantly exacerbated in liver sections from late stage PSC pa-
tient (Fig. 5b). By immunoblots, there was increased protein levels ofTable 1
Evaluation of liver and body weight, and liver to body weight ratio, serum chemistry and level
Parameters WT M
Liver weight (g) 2.0 ± 0.5 2.9
n = 6 n =
Body weight (g) 30.2 ± 1.7 29
n = 6 n =
Liver to body weight ratio (%) 6.9 ± 1.6 9.7
n = 6 n =
SGOT (Units/L) 160.8 ± 10.9 93
n = 6 n =
SGPT (Units/L) 538.3 ± 57.2 17
n = 6 n =
ALP (Units/L) b50 ± 0.0 27
n = 6 n =
TGF-β1 levels in serum (ng/ml) 4.5 ± 0.1 14
n= 3 n =
TGF-β1 levels in cholangiocyte Supernatant (ng/ml) 1.3 ± 0.1 3.1
n = 3 n =
⁎ P b .05 vs. WT mice.
# P b .05 vs. Mdr2−/−mice.vimentin, along with α-SMA and Col1a1 in PSC patients compared to
healthy controls (Fig. 5c). However, there was no significant change of
E-cadherin expression between PSC patients and healthy controls
(Fig. 5c, Supplementary Fig. 4). Morphological changes were observed
with the staining of vimentin in hPSCL compared to HIBEpiC (Fig. 5d).
Staining for CK-19 and HNF4α was used to verify the purity of the cul-
tured cells and exclude the contamination of hepatocytes (Fig. 5d).s of TGF-β1 in serum and cholangiocyte supernatant.
dr2−/− Mdr2 mismatched Mdr2−/− vimentin morpholino
± 0.3 3.2 ± 0.2 2.7 ± 0.4
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induced by TGF-β1 in vitro
Since studies have suggested that TGF-β1 can induce EMT in cul-
tured cholangiocytes, we treated HIBEpiC with TGF-β1 either alone or
in combination with control or vimentin CRISPR/Cas9 KO plasmid
[3,6,29]. Silencing of vimentinwas verified as approximately 50%knock-
down efficiency when compared with basal and control KO groups(Fig. 6a).We observed elevated expression of vimentin and reduced ex-
pression of E-cadherin in HIBEpiC treatedwith TGF-β1 alone,whichwas
significantly altered with the presence of vimentin CRISPR/Cas9 KO
plasmid (Fig. 6a). In addition, knockdown of vimentin suppressed
TGF-β1 induced expression offibrosismarkers (Col1a1 and Fn1) and se-
nescent markers (p16 and p21) in cultured HIBEpiC (Fig. 6b). Collec-
tively, these data indicate that inhibition of vimentin reduces
mesenchymal phenotype of cholangiocytes induced by TGF-β1 in vitro.
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decreased fibrotic reaction in vitro
We incubated HHSteCs with cholangiocyte supernatant collected
fromWT, Mdr2−/−, Mdr2−/− vimentin Vivo-Morpholino, and Mdr2−/−
mismatchedmice to evaluate theparacrine effect of cholangiocyte super-
natant onHSCactivation. Interestingly, therewas increased expression of
fibrosis markers (TGF-β1, Col1a1 and Fn1) and decreased expression of
E-cadherin and senescent markers (p16 and p21) in HHSteCs treated
with cholangiocyte supernatant fromMdr2−/−when comparedwith su-
pernatant fromWTmice (Fig. 7). However, gene expression was altered
in HHSteCs treated with cholangiocyte supernatant fromMdr2−/−with
vimentin Vivo-Morpholino compared with supernatant fromMdr2−/−
mice. No significant difference was observed in Mdr2−/−mismatched
mice when compared with Mdr2−/−mice (Fig. 7).4. Discussion
The main findings of the present study indicate that: (i) there
was enhanced mesenchymal phenotypes of cholangiocytes inMdr2−/−mice, which was reduced by treatment with vimentin Vivo-
Morpholino; and (ii) liver damage, ductular reaction, biliary senescence
and liver fibrosis were concomitantly decreased in Mdr2−/− mice
treated with vimentin Vivo-Morpholino. We also demonstrated that:
(i) overexpression of vimentin and other mesenchymal markers were
observed in PSC patients and hPSCL compared to healthy controls and
HIBEpiC (normal cholangiocyte lines), respectively; (ii) in vitro silenc-
ing of vimentin reduced TGF-β1-induced mesenchymal phenotypes of
HIBEpiC; and (iii) in HHSteCs treated with cholangiocyte supernatant
with reduced vimentin levels displayed decreased fibrosis and senes-
cent reaction.
EMT is a phenomenon that has been identified in several types of
chronic fibrotic disorders, where epithelial cells acquire mesenchymal
features, thereby contributing to the fibrogenic process [30,31]. EMT
has also been involved in embryonic development and tumor progres-
sion [32,33]. The key steps of EMT include loss of epithelial cell-cell ad-
hesion and the degradation of junction proteins, including E-cadherin;
and upregulation of cytoskeletal proteins belonging to the mesenchy-
mal lineage, including vimentin, S100a4 and, eventually,α-SMA [4]. Ad-
ditional changes during EMT include the generation of fibroblasts
associated with accumulation of extracellular matrix and increased
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during liver fibrosis [3,34]. In the current study, we found that
there was enhanced mesenchymal phenotypes of cholangiocytes
in Mdr2−/− compared to WTmice, which may contribute to the popu-
lation of portal fibroblasts [4,5,34]. Although our data support the
existence of cholangiocyteswith amesenchymal phenotype, it's contra-
dictory to the findings by Chu et al., who used Alfp-Cre x Rosa26-YFP
mice to achieve lineage tracing for all epithelial cells of the liver (hepa-
tocytes, cholangiocytes, and their bipotential progenitors) with yellow
fluorescent protein (YFP) [6]. They found no evidence of YFP co-
localization with the mesenchymal markers S100A4, vimentin or α-
SMA in mice models of liver fibrosis, including BDL and CCl4 treatment;
however, several factors may explain this discrepancy. First, the studies
were conducted with different animal models from the ones in our
study. Although all three models are widely used in experimental liver
fibrosis setting, Mdr2−/−mice has been recognized to share several im-
portant morphologic and pathogenetic characteristics with human PSC
[35–38]. Second, different experimental approaches were utilized to
evaluate mesenchymal traits. We realize that immunostaining itself
may cause many nonspecific signals and some mesenchymal markers
may not be cell-type specific, which limits the specificity of this tech-
nique. However, lineage tracing studies using Cre-LoxP system also
has some pitfalls. The efficiency of Cre-mediated recombination is not
100%. It is theoretically possible that mesenchymal transition might
have occurred in the non-labeled cells. Furthermore, we demonstrated
in the current study that overexpression of vimentin and decreasedCK-19 staining intensity were observed in PSC patients compared with
healthy controls. Interestingly, E-cadherin protein expression was not
decreased in PSC patients, which might be due to the abundant
E-cadherin expressed in hepatocytes. Although loss of E-cadherin has
been recognized as a hallmark of EMT, the observation of maintained
E-cadherin expression in cholangiocytes has also been demonstrated
by Yasunori et al. [31] With regard to hepatocellular carcinoma (HCC),
E-cadherin expression is commonly variable and is elevated in 40% of
HCC cases, suggesting its paradoxic roles in HCC [39–41]. Another
study has demonstrated that cholangiocytes within sites of ductular re-
action from patients with PSC, PBC and alcoholic cirrhosis showed sig-
nificant induction of S100a4, MMP2 and vimentin, suggesting that the
development of portal tract fibrosis is associated with local induction
of an EMT process [3]. However, no co-localization of CK-19 and
α-SMA were observed in human liver sections, which we believe is be-
cause only mature myofibroblasts may express α-SMA and already lost
the expression of CK-19 after migration.
The molecular mechanisms that regulate changes in EMT include
paracrine and autocrine factors (cytokines, proinflammatorymediators,
and growth factors), and several signal pathways (TGF-β, Hedgehog
and Wnt/β-catenin) [34]. Among these signaling pathways, TGF-β1 is
critical to the progression of fibrosis and the major inducer of EMT
which binds to the functional complex of TGF-β receptor family at the
cell surface, which leads to the phosphorylation of Smad2/3 [42–44].
Studies using cultured cholangiocytes have shown that TGF-β1 treat-
ment evoked a decrease in the expression of epithelial markers and
141T Zhou et al / EBioMedicine 48 (2019) 1 –14203increase in the expression of vimentin and othermesenchymalmarkers
[31,45,46]. In the current study, we found that the effects of inhibiting
vimentin in Mdr2−/− mice on mesenchymal phenotypes of
cholangiocytes and liver fibrosis were associated with decreased levels
of TGF-β1. Furthermore, cellular senescence and its associated secretion
of senescence-associated secretory phenotypes (SASP, e.g., TGF-β1, p16
and SA-β-gal) have been considered as key hallmarks of
cholangiopathies including PSC and PBC,which contributes to enhanced
liver fibrosis [12,13]. We have previously shown that TGF-β1 increases
biliary senescence by an autocrine loop, which in turn leads to the para-
crine activation of HSCs by cholangiocytes [13].
In conclusion, we have identified that vimentin Morpholino treat-
ment in Mdr2−/− mice reduces mesenchymal phenotype of
cholangiocytes, ductular reaction, biliary senescence and liver fibrosis,
and the pro-fibrotic activation of HSCs by a paracrine mechanism. Inhi-
bition of vimentin expression may be a key therapeutic target in the
treatment of cholangiopathies including PSC.
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